Oncogenic E6E7 mRNA Test
Advanced Cervical Cancer Risk Assessment
The Oncogenic E6E7 mRNA Test represents a significant advancement in cervical cancer screening and prevention strategies. This sophisticated molecular diagnostic tool specifically detects the presence of messenger RNA from high-risk human papillomavirus (HPV) strains, providing crucial insights into active viral infections that have the potential to progress to cervical cancer.
What Does the E6E7 mRNA Test Measure?
This innovative test specifically targets and measures the expression levels of E6 and E7 oncogenes from high-risk HPV types. Unlike traditional HPV DNA tests that merely detect the presence of viral genetic material, the E6E7 mRNA test identifies active viral gene expression, indicating that the virus is producing proteins known to disrupt normal cellular functions and promote cancer development.
- Detects active transcription of HPV oncogenes
- Measures viral proteins E6 and E7 expression levels
- Identifies high-risk HPV strains with oncogenic potential
- Provides quantitative assessment of viral activity
Who Should Consider This Test?
The Oncogenic E6E7 mRNA Test is particularly valuable for women in specific clinical situations where precise risk stratification is essential for optimal patient management.
Primary Candidates Include:
- Women with abnormal Pap smear results (ASC-US, LSIL, or HSIL)
- Patients with persistent HPV infections detected through DNA testing
- Women with a family history of cervical cancer
- Patients undergoing follow-up after cervical dysplasia treatment
- Women seeking comprehensive cervical cancer risk assessment
- Patients with compromised immune systems requiring enhanced monitoring
Clinical Benefits and Advantages
The Oncogenic E6E7 mRNA Test offers several significant advantages over traditional screening methods, providing both patients and healthcare providers with more precise diagnostic information.
Key Benefits:
- Enhanced Predictive Value: Higher specificity for identifying women at genuine risk of developing cervical cancer
- Reduced Unnecessary Procedures: Helps minimize overtreatment by distinguishing between transient and persistent infections
- Early Intervention Opportunities: Enables timely medical interventions before precancerous changes progress
- Comprehensive Risk Assessment: Provides detailed information about viral activity and oncogenic potential
- Improved Patient Management: Guides appropriate follow-up strategies and treatment decisions
Understanding Your Test Results
Proper interpretation of Oncogenic E6E7 mRNA test results requires consultation with your healthcare provider, but general guidance can help you understand the potential outcomes.
Possible Result Interpretations:
- Negative Result: No detectable E6E7 mRNA present, indicating low risk of cervical cancer development from current HPV infection
- Positive Result: Presence of E6E7 mRNA detected, suggesting active viral oncogene expression and increased cancer risk
- Quantitative Levels: Higher mRNA expression levels may correlate with increased oncogenic activity and progression risk
Your gynecologist or oncologist will correlate these findings with your clinical history, Pap smear results, and other diagnostic information to develop an appropriate management plan.
Test Pricing and Availability
| Test Name | Discount Price | Regular Price |
|---|---|---|
| Oncogenic E6E7 mRNA Test | $88 USD | $98 USD |
Sample Collection and Processing
Sample collection occurs on Tuesday, Thursday, or Saturday by 9:00 AM. Results are typically available the following business day (Wednesday, Friday, or Monday). The test requires a cervical swab sample collected in a specialized container with medium provided by our laboratory. Proper sample handling is critical – specimens must be refrigerated immediately after collection and maintained at 2-8°C. Freezing samples is strictly prohibited as it compromises test accuracy.
Nationwide Accessibility
GGC DNA maintains comprehensive testing facilities across the United States, ensuring convenient access to the Oncogenic E6E7 mRNA Test in all major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, San Jose, and numerous other locations.
Take Control of Your Cervical Health
Early detection through advanced molecular testing like the Oncogenic E6E7 mRNA Test provides the best opportunity for preventing cervical cancer development. This state-of-the-art diagnostic approach offers unprecedented insights into your cervical health status and cancer risk assessment.
Ready to schedule your Oncogenic E6E7 mRNA Test? Contact our dedicated healthcare team today at +1(267) 388-9828 or book your appointment online. Our experienced staff will guide you through the testing process and ensure you receive the comprehensive care you deserve.
